• • PTX-PBA prodrug design achieved markedly enhanced drug encapsulation stability and dual-drug loading efficiency, overcoming the physicochemical incompatibility that previously limited co-delivery of PTX and immune adjuvants.
• • NanoPR exhibited ROS-triggered release profiles, ensuring controlled drug release specifically in the tumor microenvironment, which is critical for minimizing systemic toxicity.
• • In 4T1 breast cancer and CT26 colon carcinoma murine models, NanoPR achieved significant tumor growth inhibition and elicited durable immune memory responses, indicating potential for long-term protection against recurrence.
• • The nanosystem effectively induced immunogenic cell death in tumor cells and promoted dendritic cell maturation and CD8+ T cell activation, bridging innate and adaptive immunity for a robust antitumor response.